meros Corporation was founded in 1994 and is based in Seattle, Washington. Omeros Corporation is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company’s clinically advanced product candidates are derived from its PharmacoSurgerytm platform designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

deCODE genetics, Inc. (deCODE) is a bio-pharmaceutical company developing and marketing products for the treatment, diagnosis, and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in therapeutic areas, and applies its discoveries in human genetics to bring to market deoxyribonucleic acid (DNA)-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. In November 2009, the Company announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware.

MacroGenics Inc. company is developing therapeutic treatments for cancer, autoimmune disorders, and infectious diseases. The company is helping researchers from National Institutes of Health and two universities to develop a fully human monoclonal antibody (single disease-cell targeting protein) treatment for the deadly West Nile virus. MacroGenics is also in late development stages for another monoclonal antibody used to treat Type 1 diabetes (also known as juvenile diabetes); the diabetes treatment has received orphan drug status, an FDA designation for rare diseases. Other targeted ailments include cancer, arthritis, and multiple sclerosis.

SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

Otsuka Pharmaceutical Co. (OPC) is a manufacturer and distributor of pharmaceuticals, clinical testing and medical equipment, and food products. The company operates six business segments specializing in branded prescriptions, over-the-counter drugs, clinical nutritionals, diagnostic substances and devices, nutraceuticals, and skin care products ("cosmedics"). OPC's medicinal products include Mikelan eye drops for glaucoma treatment and Pletaal anti-platelet treatment. The company's line of nutraceutical consumer health products include FIBE-MINI dietary fiber supplement, Calorie Mate foods, and Pocari Sweat sports drink. Otsuka Pharmaceutical is part of the very diverse Otsuka Group.

IDEXX Laboratories, Inc. company was founded in 1983 and is headquartered in Westbrook, Maine. IDEXX Laboratories, Inc. develops, designs, manufactures, and distributes products for veterinary, and food and water testing markets. It operates in three segments: Companion Animal Group (CAG), Water Quality Products (Water), and Production Animal Segment (PAS). The CAG segment provides point-of-care veterinary diagnostic products, such as instruments and consumables, and rapid assays; and information products and services, and digital radiography systems for veterinarians. This segment also offers commercial veterinary reference laboratory and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, and South Africa. The Water segment offers a range of products used in the detection of various microbiological analytes in water to government laboratories, water utilities, and private certified laboratories. The PAS segment provides diagnostic tests and related instrumentation that are used to detect diseases, and to monitor health status in production animals. This segment offers its products primarily to government laboratories, cattle, and poultry and swine producers. IDEXX Laboratories also provides products that test milk for antibiotic residues to dairy producers and processors, as well as to government and food-quality managers. In addition, the company sells point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, and ionized calcium, as well as to calculate other parameters, such as base excess and anion gap. It markets and sells its products directly, as well as through independent distributors and other resellers in the Americas, Europe, and the Asia Pacific region.

AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal treatment, as well as herbal remedies, vitamins and adjunctive therapies. Through its wholly owned subsidiary, AXM Pharma Shenyang, Inc., the Company has established a pharmaceutical operation focused on supplying the drugs and branded products in specific categories. Werke Pharmaceuticals, Inc. is the Company’s wholly owned subsidiary, which owns 100% of AXM Pharma Shenyang Inc., a wholly foreign owned enterprise (WFOE). Its product portfolio includes Asarone injectibles solution, Weifukang and Lifupeng. Weifukang is an antiseptic cream for cleansing acne and for relieving the symptoms of eczema, psoriasis and other skin irritations, such as contact dermatitis. Lifupeng (Rifampicin) is used for treatment of tuberculosis.

XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

Healthpoint, Ltd. company was founded in 1992 and is based in Fort Worth, Texas. Healthpoint, Ltd. operates as a subsidiary of DFB Pharmaceuticals, Inc. Healthpoint, Ltd., a specialty pharmaceutical company, develops and markets pharmaceutical and medical products for the treatment of chronic wounds. It focuses on the prevention and treatment of diseased and traumatized skin and related soft tissue. The company provides tissue management products, which includes sterile enzymatic debriding ointment, extracellular matrix-based wound product, bacteriostatic dressing, ointment for perineal wounds, papain-urea debriding ointment, doxepin hydrocloride cream, moisturizing dermal wound cleanser, hydrogel wound dressing, odor eliminator, powder for superficial skin infections caused by yeast, and protectant for intact and injured skin, as well as healing, debriding, and deodorizing ointment. It also offers surgical products, such as brush-free scrubbing products, surgical scrubs, waterless scrubs, healthcare personnel handwash and rub, hand and body antiseptic, one-step prep solutions, and topical anesthetic sprays. The company serves healthcare market, which includes nurses, physicians, surgeons, nursing homes, home health agencies, and office-based practices. It distributes its products through drug wholesalers and medical/surgical distributors.

Taisho Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company. Taisho Company, along with its subsidiaries and associated companies, operates in two business segment. The Self Medication segment is engaged in the research, development, manufacture and sale of self-medication pharmaceuticals, quasi drugs and food products. This segment is also involved in the provision of insurance services, logistics services, printing services, as well as real estate leasing, management and operation services. The Prescribed Medication segment is engaged in the development, manufacture and sale of prescribed pharmaceuticals. Taisho Company has 23 subsidiaries and three associated companies. The Company acquired 97.97% stake in PT Bristol-Myers Squibb Indonesia Tbk. on October 31, 2009.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.